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months ago) and were receiving GnRH with or without anti-
androgen, and had recent experience of hot ﬂushes as a result of
their therapy. A content and thematic analysis was conducted to
identify themes and categories that centred on particular phrases,
incidents and types of behaviour. RESULTS: Participants (n = 12)
aged 58–82, diagnosed on average for 5 years, receiving GnRH
agonists (100.0% Lupron, 40.0% Casodex, 20.0% Zometa)
were interviewed. The ﬁrst hot ﬂush usually occurred within 2
weeks of GnRH treatment. Participants experienced widely dif-
fering hot ﬂush event frequency and severity; from 8–10 events in
24 hours to one in 2–3 weeks. Events lasted 2 minutes to one
hour, and occurred at different times. Analyses identiﬁed that hot
ﬂushes were most commonly described in terms of ‘sweating’,
‘burning up’, and ‘perspiring’. Those who had more severe
ﬂushes also described ‘dizziness’, ‘weakness’, and ‘nausea’. Par-
ticipants found their hot ﬂush experience generally distressing
e.g. felt scared, anxious, annoyed, confused, irritated, worried.
Hot ﬂushes impacted men’s lives e.g. sleep problems, needing to
stop activities, resting, taking a cold shower. However, most
considered the hot ﬂush experience in the context of their overall
condition, some reported getting used to the experience over time
and adopting varies coping strategies. CONCLUSION: Hot ﬂush
descriptions reﬂect those previously reported in the literature,
provide additional depth to the experience from the patient’s
perspective and will inform the development of health states for
utility assessment.
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OBJECTIVE: Hodgkin’s lymphoma (HL) signiﬁcantly impacts
the health related Quality of Life (HRQoL) of patients. Treated
patients often report increased stress, fatigue, nausea, sexual
dysfunction, decreased social and emotional function, and
vocational limitations; however few studies have assessed these
domains. This review summarizes the impact of HL on hrQoL
and recommends which HRQoL constructs should be assessed in
the clinic and in clinical trials. METHODS: A systematic review
of the literature was conducted in order to better understand the
impact of HL and its treatments on HRQoL. The identiﬁed
articles were reviewed for references to HRQoL and speciﬁc tools
to assess these constructs. The major impacts of the disease and
treatment effects are compared across tools assessing these
domains. RESULTS: Some 30 published studies assessing hrQoL
in patients with HL were identiﬁed. In these 30 articles over 20
instruments were used to assess HRQoL. The most common
cancer-speciﬁc instruments employed were the EORTC QLQ-30
and various fatigue scales. No HL speciﬁc instrument was iden-
tiﬁed as being widely used. Tables summarizing the domains
covered by each instrument are provided. The EORTC and
FACT-Lym appear to provide the best coverage of relevant
HRQoL domains, however, using more than one instrument is
necessary to capture all relevant domains. CONCLUSION:
Although HL signiﬁcantly impacts HRQoL very few studies have
collected this data in a comprehensive manner. This work reviews
the literature on the HRQoL in patients with HL and provides
insights regarding the key set of HRQoL constructs that should
be assessed in the clinic and in clinical trials to best characterize
the impact of HL and treatment. Although the FACT-Lym pro-
vides good coverage of HRQoL domains in HL, additional vali-
dation work is needed to ensure the reliability and validity of the
tool in this population.
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OBJECTIVE: To estimate general public preference-based utili-
ties for standardized health states that include common responses
and toxicities observed during treatment of advanced melanoma.
METHODS: A cross-sectional study was used to elicit standard
gamble utilities for melanoma in the UK and Australia. Health
states included partial response (PR), stable disease (SD) and
progressive disease (PD). Common grade I/II toxicities (occurring
in >10% of patients) were abstracted from the literature for
dacarbazine, temozolomide, interleukin-2, fotemustine, and
interferon alpha2b. These may also apply for ipilumumab, a
developmental immunotherapy. Health state descriptions were
based on WHO response deﬁnitions, Common Toxicity Criteria
for Adverse events v3, and feedback from ﬁve clinical experts and
three quality-of-life researchers. RESULTS: Utilities were elicited
from 110 participants in the UK (n = 64) and Australia (n = 56).
Mean utilities estimated (for UK vs. Australian respondents)
were as follows: PR (0.85 vs. 0.89); SD (0.77 vs. 0.80); PD (0.59
vs. 0.44); and best supportive care (0.59 vs. 0.44). Utility decre-
ments associated with the toxicities were: hair loss (-0.03); skin
reaction (-0.03 vs. -0.08); diarrhea (-0.06 vs. 0.12); toxicity,
but indication that treatment may be working (-0.06 vs. -0.08);
nausea/vomiting (-0.07 vs. -0.13); ﬂu-like syndrome (-0.09 vs.
-0.13); stomatitis (-0.10 vs. -0.15); 1-day out/inpatient care for
grade 3/4 toxicity (-0.11 vs. -0.15); symptomatic melanoma
(-0.11 vs. -0.22); and hospitalization for grade 3/4 toxicity
(-0.13 vs. -0.22). CONCLUSION: The development process for
these standardized health states for advanced melanoma can
serve as a model for developing disease-speciﬁc health states
that incorporate both intended treatment responses and adverse
events. PR and SD are preferred, and symptomatic melanoma
and hospitalization for toxicity yield the highest disutilities. The
method of decrementing utility values by subtracting toxicity
utility weights holds promise for assigning utilities to serious
diseases treated with toxic therapies.
PCN72
DISABILITY AND HEALTH-RELATED QUALITY OF LIFE IN
LONG-TERM SURVIVORS OF CANCER IN CHILDHOOD IN
BRAZIL: AN ASSESSMENT OFTHE CONSTRUCTVALIDITY OF
THE HEALTH UTILITIES INDEX (HUI3)
Horsman JR1, Shimoda S2, Furlong W3, Barr RD4, De Camargo B2
1Health Utilities Inc, Dundas, ON, Canada, 2Centro De Tratamento E
Pesquisa, Sao Paulo, SP, Brazil, 3McMaster University and Health
Utilities Inc, Hamilton, ON, Canada, 4McMaster University, Hamilton,
ON, Canada
OBJECTIVE: There is limited experience with patient-reported
health status and health-related quality of life (HRQL) in survi-
vors of cancer in childhood in low-income countries. The purpose
of this study was to collect these measurements in Brazil, test
hypotheses about differences among diagnostic groups, and
compare the results with those from other countries in an overall
assessment of the construct validity of the HUI3. METHODS:
Survivors were eligible if: diagnosed with cancer in childhood;
attending the long-term follow-up clinic for one treatment center;
at least 8 years off therapy; cancer free, literate; and at least
13 years of age. Health status measurements were collected in
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the clinic using a Brazilian Portuguese Health Utilities Index
self-report questionnaire. Responses were converted to attribute
levels, and utility scores for morbidity in individual health
attributes and for overall HRQL, using standard HUI Decision
Tables and Utility Functions. Standard t-tests and 1-way ANOVA
were used to analyze HUI3 utility scores within and across diag-
noses and between countries. HUI3 overall HRQL scores were
categorized to mild / moderate / severe disability (1.00 = No
disability, 0.89–0.99 = Mild, 0.70–0.88 = Moderate, <0.70 =
Severe disability). RESULTS: A total of 138 consecutive survivors
participated in the survey. More than 71% reported some disabil-
ity (mild-moderate-severe). More than one-third reported some
cognitive disability and/or pain while approximately one-quarter
reported problems with vision, speech or emotion. As hypoth-
esized, retinoblastoma survivors had signiﬁcant visual morbidity
(p = 0.048). Survivors of germ cell tumors had signiﬁcant pain
morbidity (p = 0.003) and lowest meanHRQL utility score (0.49)
among the diagnostic groups. HRQL means of survivors were
similar (p > 0.05) among countries (Brazil, Canada, Central
America, Uruguay) within diagnostic groups of acute lymphoblas-
tic leukemia and hodgkin’s disease. CONCLUSION: The results
show that the Brazilian survivors experience a wide range of
disabilities and impaired HRQL similar to those reported in other
countries and afﬁrm the construct validity of the HUI3.
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OBJECTIVE: To determine the difference in survival quality of
patients treated according to two major treatment strategies for
ALL in childhood, for use in a cost-utility study. METHODS:
Children diagnosed with ALL between 1985 and 2003, and
treated in one of ﬁve centers according to a DFCI or BFM-based
protocol, were eligible if they were alive at least two years
post-therapy. Parents of eligible survivors, in a cross-sectional
survey, were asked to complete a Health Utilities Index (HUI)
15-item self-complete questionnaire with a ‘past 1-week’ recall
period. HUI3 health-related quality of life (HRQL) and single-
attribute scores were determined for each patient according to
standard algorithms. Chi-square was used to test for differences
in confounding factors between study groups: gender, and age at
diagnosis (in quintiles). Differences in mean HRQL and single-
attribute scores between DFCI and BFM groups were tested
using one-way ANOVA. Statistical signiﬁcance was set at
p < 0.05. RESULTS: 612 parent assessments were available for
analysis: 463 for DFCI survivors and 188 for BFM survivors. No
signiﬁcant differences between DFCI and BFM survivors were
detected for proportion of males and females (p > 0.079), and
age at diagnosis (p > 0.243). There were no signiﬁcant differences
detected between DFCI and BFM survivors in mean single-
attribute or HRQL scores (p > 0.176). The mean HRQL score
was 0.90 (SD = 0.166) for DFCI survivors, 0.92 (SD = 0.140) for
BFM survivors, and 0.91 (SD = 0.159) for the pooled set of
survivors. CONCLUSION: Clinical research has reported previ-
ously that there is no signiﬁcant difference in mortality rates
between DFCI and BFM treatment strategies. These HRQL
results indicate that survivors of these treatment strategies also
do not experience a difference in quality of survival. Future work
for the cost-utility study will focus on the incremental HRQL of
patients during phases of active therapy and the costing of
hospital-based health care services.
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OBJECTIVE:Determine the impact of testing for high prevalence,
low penetrance gene variants associated with colorectal cancer
(polymorphisms, haplotypes) on a person’s quality of life (QOL),
health habits, and cancer screening intentions.METHODS: First-
degree relatives of colorectal cancer patients and a matched group
of persons without a family history of colorectal cancer from the
Colorectal Cancer Familial Registry—a population-based registry
in Washington State—were invited in 2006–7 to participate in a
web-based survey of testing for gene variants associated with
colorectal cancer risk. Participants were asked how such tests
might inﬂuence their QOL, health habits, and intent to obtain
colorectal cancer screening. RESULTS: A total of 310 relatives
and 170 persons without a family colorectal cancer history com-
pleted the questionnaire. For the positive genetic test scenario,
69% of respondents stated they would be “somewhat worried”;
18% said they would be “very worried.” QOL measured by the
standard gamble for the carrier state was modestly lower than
current health; the difference was signiﬁcant only for relatives (no
relatives with colorectal cancer 0.89 vs. 0.88, p = 0.11; relatives
with colorectal cancer 0.90 vs. 0.88, p = 0.02). The difference in
QOL was not signiﬁcant after adjustment for sociodemographic
and health factors. In the positive gene test scenario, 30% of
respondents stated they would change their diet substantially,
25% would increase exercise, and 43% would start colorectal
cancer screening. Relatives of colorectal cancer patients did not
differ signiﬁcantly from those without a family history in their
reported intent to change these behaviors. CONCLUSION:
Testing for high prevalence gene variants associated with colorec-
tal cancer risk may increase cancer worry while only modestly
inﬂuencing overall QOL. Testing could improve cancer preventive
health habits and colorectal cancer screening adherence. The
ﬁndings suggest that testing might reduce colorectal cancer inci-
dence, particularly among those at higher risk for colorectal
cancer.
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OBJECTIVE: Adult chronic immune thrombocytopenic purpura
(ITP) is characterized by autoimmune-mediated platelet destruc-
tion and suboptimal platelet production. Signs and symptoms
can range from bruising to gastrointestinal and intracranial
bleeding. The disease may therefore impact one’s health-related
quality of life (HRQoL). We quantiﬁed the burden of ITP on
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